Developers: | MiRus |
Date of the premiere of the system: | August 2024 |
Branches: | Pharmaceuticals, Medicine, Healthcare |
2024: Product Announcement
In early August 2024, an implant was presented for the treatment of the cervical and upper thoracic spine without repeated operations. Regulators have awarded the company's Europa device MiRus breakthrough technology status based on unprecedented clinical trial results.
MiRus is developing its own new biomaterials and implants that should transform surgery by making surgeries less invasive and implants safer and more durable. The new system, based on MiRus branded rhenium alloys, is designed to treat injuries and diseases of the cervical and upper thoracic spine. The developers of MiRus reported that the system is based on the production of MoRe rods with a diameter of 2.9 mm, which are much smaller in size than the rods currently available.
The smaller diameter Europa rod allows the use of special transpedicular screws, which makes it possible to carry out less invasive surgical operations. In addition, such a system is more suitable for patients of small stature. MiRus says MoRe rods provide superior levels of stiffness, strength and resistance to metal fatigue development despite the smaller diameter. Such unique properties reduce the risk of spinal rod fractures compared to systems already available on the market.
Currently, the rates of rejection or fracture of spinal implants and the need for repeated operations remain unacceptably high, said Jordan Bauman, the company's vice president of regulation and product quality. - Thanks to Europa's new system, spinal surgeons will be able to perform less invasive surgeries on the cervical thoracic spine with more reliable results.[1] |